Literature DB >> 15251127

The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers.

Fabienne Mackay1, Stuart G Tangye.   

Abstract

Signaling through the B cell antigen receptor promotes activation and survival of mature B cells. B cell-activating factor belonging to the tumor necrosis factor family (BAFF) is another critical survival factor for B cells, and is also necessary for B cell maturation. Abnormal production of BAFF disturbs immune tolerance by allowing the survival of autoreactive B cells, thus triggering autoimmune disorders. BAFF can also have an important impact on B cell malignancies. In contrast to normal B cells, malignant B cells show uncontrolled cell proliferation. BAFF levels are elevated in the serum of patients with systemic autoimmune diseases, and, importantly, in patients with B-lymphoid malignancies. Furthermore, BAFF is produced by malignant B cells and acts as an essential autocrine survival factor. The strong dependence of certain lymphoid cancer cells on BAFF might be a point of vulnerability, which offers exciting new therapeutic possibilities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15251127     DOI: 10.1016/j.coph.2004.02.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  41 in total

1.  Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.

Authors:  Montserrat Cols; Carolina M Barra; Bing He; Irene Puga; Weifeng Xu; April Chiu; Wayne Tam; Daniel M Knowles; Stacey R Dillon; John P Leonard; Richard R Furman; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

Review 2.  [Autoantibodies and antibody-secreting cells].

Authors:  F Hiepe; T Dörner
Journal:  Z Rheumatol       Date:  2005-09       Impact factor: 1.372

3.  Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients.

Authors:  Suresh Pallikkuth; Sudheesh Pilakka Kanthikeel; Sandra Y Silva; Margaret Fischl; Rajendra Pahwa; Savita Pahwa
Journal:  J Allergy Clin Immunol       Date:  2011-07-12       Impact factor: 10.793

4.  A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys.

Authors:  Yulia Vugmeyster; Dhaya Seshasayee; Wesley Chang; Anahid Storn; Kathy Howell; Susan Sa; Tenea Nelson; Flavius Martin; Iqbal Grewal; Ellen Gilkerson; Ben Wu; Jeff Thompson; Barbara N Ehrenfels; Song Ren; An Song; Thomas R Gelzleichter; Dimitry M Danilenko
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

5.  NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells.

Authors:  Yoshiteru Sasaki; Dinis P Calado; Emmanuel Derudder; Baochun Zhang; Yuri Shimizu; Fabienne Mackay; Shin-ichi Nishikawa; Klaus Rajewsky; Marc Schmidt-Supprian
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-28       Impact factor: 11.205

Review 6.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 7.  Host genetics in follicular lymphoma.

Authors:  James R Cerhan
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-05       Impact factor: 3.020

8.  Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.

Authors:  Daniel J Medina; Lauri Goodell; John Glod; Céline Gélinas; Arnold B Rabson; Roger K Strair
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

Review 9.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.